A value stock is generally a company that trades at a price lower than its fundamental value or what its performance suggests ...

Latest move to cut funding for vaccines is not down to US health secretary. It is part of Trump’s wider war on science.

Doting father-of-two John O'Neill from Althorne, Essex, had a one in 50,000 reaction to the AstraZeneca jab in May 2021 that ...

Flutter Entertainment (FLTR) upped full-year guidance after a solid second quarter, with group revenue up 16 per cent to $4.2bn (£3.1bn) and adjusted Ebitda climbing 25 per cent to $919mn. Average ...

The federal government’s decision to slash $500 million in funding for mRNA vaccine research has sparked concern among health ...

GSK provides update on US settlement of CureVac/BioNTech mRNA patent litigation: London, UK Saturday, August 9, 2025, 10:00 Hrs [IST] GSK plc announces that, in connection with th ...

The Score is a weekly review of the biggest stock moves and the news that drove them. Here is this week's installment: ...

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

GSK is set to receive up to $500 million and 1% royalties on future vaccine sales following the settlement of a US patent dispute between CureVac NV, Pfizer, and BioNTech SE.

In statements to the USA TODAY Network, both the University of Rochester Medical Center, or URMC, and Regeneron noted they don't receive federal funding connected to the mRNA research cuts announced ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

US Health Secretary Robert F. Kennedy Jr. has slashed government spending on mRNA vaccine research. Experts warn it will boost global vulnerability to future pandemics.